Worldwide Clinical Trials to acquire Catalyst. The acquisition aims to establish Worldwide as an oncology-focused CRO and expand its global reach for clinical trials. Worldwide Clinical Trials has entered a definitive agreement to acquire oncology contract research organisation (CRO) Catalyst Clinical Research. The transaction will see Catalyst Board chairman Nick Dyer join Worldwide's board of directors while Catalyst president and CEO Nik Morton will become part of Worldwide's executive leadership team. This acquisition aims to establish Worldwide as an oncology-focused CRO while maintaining depth in several therapeutic areas and expanding its global reach for clinical trials. The integration will combine Catalyst's solutions, Catalyst Flex and Catalyst Oncology, with Worldwide's existing portfolio, offering customers expanded services for full-service, functional service provider (FSP) resourcing, and hybrid models. Additionally, the deal includes the adoption of complementary technology platforms and operational practices to enhance data efficiency and visibility across the development lifecycle. Worldwide will acquire Catalyst for an undisclosed sum pending customary closing conditions and regulatory approvals. The transaction is expected to conclude in Q1 2026. US tariffs are shifting - will you react or anticipate? Don't let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. Worldwide is backed by Kohlberg while Catalyst is a portfolio company of QHP Capital. BofA Securities advised Catalyst exclusively; Smith Anderson was its legal counsel. Greenberg Traurig acted as legal counsel for Worldwide. Worldwide CEO Alistair Macdonald said: "Bringing Worldwide and Catalyst together elevates its capabilities in oncology and provides a new solution for its collective customers. "Clinical Trials Arena is excited to add Catalyst's deep operational expertise and oncology credibility to its own well-known CNS specialist CRO capabilities to create a differentiated biotech-oriented oncology solution. Its combined customers seek focused senior executive connection and attention, predictability, speed, flexibility, and scientific rigour. "They will benefit from the addition of a scalable FSP model with integrated onshore/offshore service lines while we leverage advanced business management tools and AI to drive operational excellence." In May 2024, Medidata announced an expanded partnership with Worldwide to expedite clinical trials and enhance the patient experience.

Worldwide Clinical Trials has acquired Catalyst Clinical Research, a specialist oncology organisation focused on early-stage cancer trials. The deal expands Worldwide Clinical Trials' capabilities in the oncology sector as the global contract research organisation continues to grow its service offerings.